WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 6, 2017, Pages 1688-1695

  Mushtaq, Shazad ^a   Vickers, Anna ^a   Woodford, Neil ^a   Livermore, David M ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; CYCLOOCTANE DERIVATIVE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; UNCLASSIFIED DRUG; WCK 4234; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; CARBAPENEMASE; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROBACTERIACEAE; ENZYME ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; ACINETOBACTER INFECTION; BIOSYNTHESIS; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEMS; CYCLOOCTANES; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 85021660814     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx035     Document Type: Article

References (27)

1. Drawz SM, Papp-Wallace KM, Bonomo RA. New b-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 2014; 58: 1835-46
2. Zasowski EJ, Rybak JM, RybakMJ. The b-lactams strike back: ceftazidimeavibactam. Pharmacotherapy 2015; 35: 755-70
3. Livermore DM, Mushtaq S, WarnerMet al. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 2017; 72: 1373-85
4. Morinaka A, Tsutsumi Y, Yamada M et al. OP0595, a new diazabicyclooctane: mode of action as a serine b-lactamase inhibitor, antibiotic and b-lactam'enhancer'. J Antimicrob Chemother 2015; 70: 2779-86
5. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4
6. King AM, King DT, French S et al. Structural and kinetic characterization of diazabicyclooctanes as dual inhibitors of both serine-b-lactamases and penicillin-binding proteins. ACS Chem Biol 2016; 11: 864-8
7. Poirel L, Héritier C, Tolün V et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22
8. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with b-lactams against Gram-negative bacteria, including OXA-48 b-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39: 86-9
9. Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 2013; 68: 2286-90
10. Turton JF, Woodford N, Glover J et al. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. JClinMicrobiol 2006; 44: 2974-6
11. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-92
12. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized b-lactamases. Antimicrob Agents Chemother 2004; 48: 1313-9
13. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Tenth Edition: Approved Standard M07-A10. CLSI, Wayne, PA, USA, 2015
14. Yang YJ, Livermore DM, Williams RJ. Chromosomal b-lactamase expression and antibiotic resistance in Enterobacter cloacae. J Med Microbiol 1988; 25: 227-33
15. Livermore DM. Interplay of impermeability and chromosomal b-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-8
16. Kamolvit W, Sidjabat HE, Paterson DL. Molecular epidemiology and mechanisms of carbapenem resistance of Acinetobacter spp. in Asia and Oceania. Microb Drug Resist 2015; 21: 424-34
17. Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit CareMed 2015; 36: 74-84
18. Munoz-Price LS, Poirel L, Bonomo RA. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96
19. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantommenace. J Antimicrob Chemother 2012; 67: 1597-606
20. Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-b-lactamase (NDM)-mediated carbapenem resistance. JMedMicrobiol 2013; 62: 499-513
21. Doumith M, Ellington MJ, Livermore DM et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 2009; 63: 659-67
22. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-36
23. Higgins PG, Dammhayn C, Hackel M et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 233-8
24. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40
25. Bush K. A resurgence of b-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 2015; 46: 483-93
26. Livermore DM, Chen HY. Potentiation of b-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC b-lactamases. J Antimicrob Chemother 1997; 40: 335-4
27. Zhou XY, Kitzis MD, Gutmann L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 1387-9